Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19

2Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

Objective: To assess the effect of chloroquine and hydroxychloroquine on cytokine release syndrome (CRS) in adult patients with coronavirus disease 2019 (COVID-19) having mild to moderate symptoms. Methods: This blinded, placebo-controlled, randomized study was conducted in the Department of Medicine, Pak Emirates Military Hospital Rawalpindi, from June 1–15, 2020. A total of 150 hospitalized patients were enrolled after diagnoses with COVID-19 through reverse transcription polymerase chain reaction (RT-PCR). They were divided into three groups: Hydroxychloroquine plus general care (HGC, n=50), chloroquine plus general care (CGC, n=50), and only general care (OGC, n=50). The HGC group received treatment with hydroxychloroquine 400 mg every 12 hours for day one and 200 mg for the next 4 days. The CGC group received treatment with chloroquine 250 mg every 12 hours for 7 days. The OGC group was kept as a control with only general care. After 12 days, the patients were screened for development of CRS through detection of interleukin 6 (IL-6) in serum samples by using Roche cobas e411 electrochemiluminescence immunoassay analyzer. Results: The mean duration from onset of symptoms to randomization was 7.65 days (SD = 3.287 days; range, 2-15 days). The mean age of patients was 37.57 (range 19-63) years. Results showed that out of a total 150 patients, only 10 patients (6%, mean=1.93, CI=1.89-1.97, P=0.651) developed CRS in all study groups. Four patients (8%) developed CRS in the HGC group, 2 patients (4%) in the CGC group, and 4 patients (8%) in the OGC group. There was no significant difference in the mean level of CRS among study groups. Conclusion: Administration of hydroxychloroquine and chloroquine has no effect in reducing the development of CRS in patients with COVID-19 having mild to moderate symptoms.

References Powered by Scopus

COVID-19: consider cytokine storm syndromes and immunosuppression

7223Citations
N/AReaders
Get full text

A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19

4016Citations
N/AReaders
Get full text

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

2029Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies

12Citations
N/AReaders
Get full text

Cross-sectional evaluation of medical reversals among National Institute of Health guideline practices implemented during the COVID-19 pandemic: how often did experts err in a time of crisis?

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ahmad, B., Hassan, N. U., Sehar, B., Zeb, F., Nayab, D., & Siddiqui, F. A. (2021). Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19. Clinical Medicine and Research, 19(4), 179–182. https://doi.org/10.3121/cmr.2021.1659

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

60%

Researcher 3

30%

Lecturer / Post doc 1

10%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

40%

Pharmacology, Toxicology and Pharmaceut... 2

20%

Nursing and Health Professions 2

20%

Engineering 2

20%

Save time finding and organizing research with Mendeley

Sign up for free